Jake A Kloeber

List of Publications by Year
in descending order

29	594	687363 13	713466 21
papers	citations	h-index	g-index

30	30	30	1028
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Homologous recombination into the eosinophil peroxidase locus generates a strain of mice expressing Cre recombinase exclusively in eosinophils. Journal of Leukocyte Biology, 2013, 94, 17-24.	3.3	85
2	DNA end resection and its role in DNA replication and DSB repair choice in mammalian cells. Experimental and Molecular Medicine, 2020, 52, 1705-1714.	7.7	72
3	Expression of the secondary granule proteins major basic protein 1 (MBP-1) and eosinophil peroxidase (EPX) is required for eosinophilopoiesis in mice. Blood, 2013, 122, 781-790.	1.4	68
4	Eosinophil-derived IL-13 promotes emphysema. European Respiratory Journal, 2019, 53, 1801291.	6.7	47
5	Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia, 2018, 32, 1838-1841.	7.2	42
6	Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. Blood, 2021, 137, 2463-2480.	1.4	35
7	MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING. Cancer Discovery, 2021, 11, 2726-2737.	9.4	35
8	Eosinophil-dependent skin innervation and itching followingÂcontact toxicant exposure in mice. Journal of Allergy and Clinical Immunology, 2015, 135, 477-487.e1.	2.9	31
9	ASTE1 promotes shieldin-complex-mediated DNA repair by attenuating end resection. Nature Cell Biology, 2021, 23, 894-904.	10.3	28
10	The deubiquitinase USP36 Regulates DNA replication stress and confers therapeutic resistance through PrimPol stabilization. Nucleic Acids Research, 2020, 48, 12711-12726.	14.5	26
11	Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. Nature Cell Biology, 2021, 23, 1199-1211.	10.3	22
12	Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism inBRAF-Mutated Multiple Myeloma. Clinical Cancer Research, 2021, 27, 6432-6444.	7.0	18
13	USP52 regulates DNA end resection and chemosensitivity through removing inhibitory ubiquitination from CtIP. Nature Communications, 2020, 11, 5362.	12.8	16
14	Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma. Leukemia, 2022, 36, 1078-1087.	7.2	13
15	USP13 regulates the replication stress response by deubiquitinating TopBP1. DNA Repair, 2021, 100, 103063.	2.8	10
16	m6A demethylation of cytidine deaminase APOBEC3B mRNA orchestrates arsenic-induced mutagenesis. Journal of Biological Chemistry, 2022, 298, 101563.	3.4	10
17	Critical DNA damaging pathways in tumorigenesis. Seminars in Cancer Biology, 2022, 85, 164-184.	9.6	8
18	The deubiquitinase USP7 regulates oxidative stress through stabilization of HO-1. Oncogene, 2022, 41, 4018-4027.	5.9	8

#	Article	IF	Citations
19	LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombinationâ€mediated DNA double strand break repair. Clinical and Translational Medicine, 2021, 11, e341.	4.0	7
20	RNF19A-mediated ubiquitination of BARD1 prevents BRCA1/BARD1-dependent homologous recombination. Nature Communications, 2021, 12, 6653.	12.8	7
21	FoxM1 insufficiency hyperactivates Ect2â€“RhoAâ€“mDia1 signaling to drive cancer. Nature Cancer, 2020, 1, 1010-1024.	13.2	6
22	Determining resistance mechanisms in BRAF-mutated multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e22.	0.4	0
23	Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma. Blood, 2019, 134, 4350-4350.	1.4	0
24	Determining Resistance Mechanisms in BRAF-mutated Multiple Myeloma. Blood, 2019, 134, 316-316.	1.4	0
25	Single Cell RNA-Seq Reveals Deranged Developmental Hierarchy with Coexisting Oncogenic States and Immune Evasion Programs in ETP T-ALL. Blood, 2019, 134, 3953-3953.	1.4	0
26	Enhancer Rewiring Dependent Switch from BCL2 to MCL1 Dependency Predicts NOTCH1 Inhibition Response in T-ALL. Blood, 2019, 134, 3948-3948.	1.4	0
27	Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy. Blood, 2019, 134, 3091-3091.	1.4	0
28	Immunological Consequences of Lenalidomide with and without Dexamethasone in Newly Diagnosed Multiple Myeloma. Blood, 2019, 134, 3070-3070.	1.4	0
29	Maturity State and MCL-1 Dependence Predetermines Response to NOTCH1 Inhibition in T-ALL. Blood, 2021, 138, 3484-3484.	1.4	0